ArticleHuman vaccines & immunotherapeutics2025
Analysis of a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Beijing of China.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report and analyze a case of pilomatricoma in an adolescent after receiving recombinant hepatitis B vaccine (CHO cell) in Chaoyang District of Beijing and to evaluate the causality between the disease and vaccination. Based on the professional branch of this case, we organized a seminar and we invited specialists in vaccinology, epidemiology, dermatology, infectiology, and immunology to participate in the conference. Specialists evaluated the relevance and causality between the vaccination and disease. The clinical diagnosis of the adolescent was pilomatricoma after receiving recombinant hepatitis B vaccine (CHO cell) which could not be disregarded as an adverse reaction following immunization. Although rare, there is a possibility of developing pilomatricoma after vaccination. This suggests that the implementation process of vaccination should be standardized and that the injection site after vaccination should be nursed properly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.